Read more about Investors turn to pharma stocks amid market crash; Nifty Pharma gains 1.5% on Business Standard. Among individual stocks, Lupin zoomed 3.4 per cent in the intra-day trade and hit a high of Rs 1,060, Sun Pharmaceuticals advanced 2 per cent, and Dr Reddy s Labs gained 1.7 per cent.
Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options. It has fast onset of action and promising efficacy., , sun pharmaceuticals, drug Brivaracetam, dcgi, Anti-Epilepsy Drug
NEW DELHI: Nifty s consolidation run continued to the third consecutive day as the headline index formed a bearish candle on the daily chart. The 50-pack bluechips underperformed the broader market as the rally continued in the midcap and smallcap space.
Ajit Mishra, VP - Research, Religare Broking said, In absence of any major trigger, we may see further consolidation in markets. Meanwhile, the focus should be on position management. Nifty has the next major support around the 14,850-14,950 zone. Nifty made a move towards the mentioned resistance zone of 15,245-15,315. Since the move was lacking strength, the selling started after testing the lower range of 15,245, which eventually resulted in a decent intraday profit booking. Now, although the market looks a bit tentative, it is nowhere close to the trend reversal or sell off. Rather, it needs to be construed as a minor profit booking only, said Sameet Chavan, Chief Analyst-Technical and Derivatives, Angel Broking.